Desktop Genetics Ltd.

Desktop Genetics helps scientists discover, understand and treat the root genetic causes of human diseases. Since 2012, we have supported thousands of labs around the world with best-in-class CRISPR genome editing design and analysis technology, across basic research, drug discovery, translational research and IND-enabling studies.

We believe the best science drives the best experimental outcomes. To realise the promise of game-changing genome editing therapies, we must adopt the best tools for the job. This is why at Desktop Genetics we have developed a suite of cutting-edge software products and technology-enabled services to power innovative and successful genome editing research.

At the core of our products and services lies the DESKGEN AI. The DESKGEN AI is a machine-learning platform for designing CRISPR experiments with maximum efficiency while minimising unwanted side-effects (also known as ‘off-target’ effects). This platform is the result of 4 years of research and development, leveraging what we believe to be one of the largest databases of empirical genome editing data in the world.

Desktop Genetics' tools and technologies are used by thousands of scientists in organisation around the world, including 4 of the top 5 blue chip pharmaceutical companies and world-renowned institutions such as the University College London Great Ormond Street Institute of Child Health, the Netherlands Cancer Institute, and the Copenhagen Center for Glycomics. We are proud to support the development of advanced genome-editing applications through our work.

In June 2018 Desktop Genetics was acquired by Celixir plc, a pioneering company founded by Nobel laureate Sir Martin Evans and Ajan Reginald for the development of cell and gene therapies to treat incurable or poorly treated diseases.